Oryzon Genomics SA (PK) (ORYZF) Cotización

Oryzon sube un 40% tras anunciar resultados clínicos en un fármaco contra la leucemia

Las acciones de Oryzon Genomics han cerrado la sesión de este miércoles con una subida del 40,45%, hasta 4,1 euros, después de que la empresa anunciase la presentación de resultados clínicos acerca de un fármaco para combatir la leucemia mieloide aguda.

Miércoles, 16 de Noviembre de 2016 - 17:48 h.
La empresa, especilizada en la fase clínica de epigenética para el desarrollo de terapias contra enfermedades no resueltas, ha anunciado esta mañana a la Comisión Nacional del Mercado de Valores (CNMV) que presentará datos clínicos preliminares sobre seguridad y eficacia de su fármaco en investigación ORY-1001.

Este fármaco juega un papel significativo en el desarrollo del cáncer, al correlacionar con la base genética de las células tumorales y al poder tener capacidad para inhibirlas de forma selectiva.

En concreto, Oryzon ha anunciado que presentará resultados sobre un inhibidor selectivo de LSD1 en el 58 Congreso y Exposición Anual de la Sociedad Americana de Hematología (American Society of Hematology, ASH), que tendrá lugar del 3 al 6 de diciembre en San Diego (California).

ORY-1001 se administra por vía oral a los pacientes y ataca a las células madre de leucemia mieloide aguda (LMA), una subpoblación de células cancerígenas probablemente responsables de las frecuentes recaídas de esta enfermedad


http://www.invertia.com/noticias/oryzon-sube-anunciar-resultados-clinicos-farmaco-leucemia-3166505.htm

Oryzon recibe 0,74 millones para el desarrollo de inhibidores epigenéticos

22/12/2016 - Agencia EFE

Oryzon, compañía catalana especializada en el desarrollo de fármacos experimentales, ha recibido ayudas públicas por valor de 740.000 euros, que destinará al desarrollo de su cartera de inhibidores epigenéticos frente a indicaciones inflamatorias.

En un comunicado, la empresa ha especificado que la concesión de esta ayuda se materializará en forma de préstamo a interés reducido por parte del Ministerio de Economía y Competitividad, una participación que se completará con Fondos FEDER procedentes de la Unión Europea.

Asimismo, ha indicado que esta ayuda cubrirá parcialmente los costes del proyecto titulado "Regulación epigenética de la respuesta inflamatoria", que cuenta con la colaboración de diversas instituciones académicas como el Instituto Cajal de Madrid y el Instituto López Neyra de Granada, ambos pertenecientes al CSIC; la Fundación Bosch i Gimpera, asociada a la Universidad de Barcelona; y la Universidad Autónoma de Barcelona.

El proyecto, que dispone de un presupuesto total de 1,2 millones de euros, se establece con una duración de 33 meses, ya que se inició el pasado mes de abril y se espera que finalice en el mes de diciembre del año 2018.

Las instituciones públicas participantes en el proyecto recibirán en total una ayuda de 380.000 euros en forma de subvención no reembolsable, que destinarán al desarrollo de actividades de investigación dirigidas a evaluar el potencial de los inhibidores de Oryzon en distintas patologías inflamatorias.

El presidente y consejero delegado de Oryzon, Carlos Buesa, ha mencionado que "este consorcio público-privado permitirá la puesta a punto de modelos y herramientas de utilidad para la evaluación del potencial terapéutico de los inhibidores de LSD1 y otros moduladores epigenéticos en enfermedades inflamatorias y autoinmunes".

Además, ha apuntado que este es un campo que la firma ya está explorando con ORY-2001, el primer compuesto epigenético en exploración para el tratamiento de la Esclerosis Múltiple, y ha añadido que está previsto que este compuesto finalice la Fase I en los próximos meses.

Fundada en Barcelona el año 2000, Oryzon es una compañía biofarmacéutica con oficinas en Barcelona, Cambridge y Massachusetts.

http://www.finanzas.com/noticias/economia/20161221/oryzon-recibe-millones-para-3540976.html

Oryzon Genomics Announces Presentation and Panel Discussion at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum

BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, is scheduled to present at the SACHS Associates 1st Annual Neuroscience BioPartnering & Investment Forum, being held February 23, 2016 at the New York Academy of Sciences in New York City.

Dr. Buesa’s presentation on the company’s strategy and development pipeline will take place on Tuesday, February 23rd 2016 at 14:55 pm EST. In addition, Dr. Buesa will also be a part of the Advances in Alzheimer’s Disease panel which will be held at 11:05 am EST.

Dr. Buesa commented, “We are excited to be presenting at the 1st Annual Neuroscience BioPartnering & Investment Forum. The presentation and the panel will provide us with an excellent opportunity to showcase Oryzon’s capability in developing potentially effective therapies through our epigenetics platform.”

The 1st Annual Neuroscience BioPartnering & Investment Forum will focus on key areas of neurodegenerative diseases and pain management. The event will feature special panels and company presentations. Key audiences at this event consist of analysts from the investment community, researchers and senior executives from pharma and biotech companies. The forum is an excellent platform to highlight investment and partnership opportunities.

About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015), is a clinical stage biopharmaceutical company considered the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon’s LSD1 program is currently covered by 19 patent families and has rendered two compounds in clinical trials . In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.


http://finance.yahoo.com/news/oryzon-genomics-announces-presentation-panel-130000351.html

Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
The Company Will Also Present the Latest Advances in Its LSD1 Programs at the 8th Annual Biotech Showcase


BARCELONA, Spain and CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, will attend the 34th Annual J.P. Morgan Healthcare Conference on January 11–15, 2016 at the Westin St. Francis in San Francisco to discuss with industry leaders the potential of epigenetics in devastating diseases.

The company will also participate at the Biotech Showcase 2016 event where it will present the latest advances of its Epigenetic programs with special focus on its Alzheimer’s disease program ORY-2001. The presentation will be held in Room Mission I on Track B at the Parc55 Wyndham Union Square Hotel on Wednesday, January 13 at 2:00 PM PST.

The J.P. Morgan Healthcare Conference brings together industry leaders, financial sponsors and investors to explore innovation and market trends in the pharmaceutical industry. Every January San Francisco attracts additional parallel conferences and multilateral activities between all actors in the industry in a week that is widely viewed as setting the tone for the coming year. An example is the Biotech Showcase™ conference, one of the largest annual international healthcare conferences where Oryzon traditionally starts every year its calendar of public presentations.

Epigenetics is one of the most innovative areas in the industry and Oryzon will have the opportunity to discuss the prospects of its clinical programs with industry leaders and investors for the first time as a public company. “We are very excited to be attending the J.P. Morgan Conference as well as presenting at the 8th Annual Biotech Showcase. These events attract industry experts as well as the financial community. We look forward to the opportunity to highlight Oryzon’s accomplishments and development plans for the upcoming year,” commented Dr. Buesa.

Biotech Showcase™ is an investor and networking conference dedicated to providing an excellent opportunity to private and public biotechnology and life sciences companies to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare conferences. The event attracts industry leaders, innovators, company executives, investors, sector analysts and bankers.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015), is a clinical stage biopharmaceutical company considered the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon’s LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions.

Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public.

Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.